论文信息 - Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments. - 字舞流文

Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments.

B. Chowbay | Sze Sing Lee | Sylvia Chen | W. Leong

[1] Weekly national respiratory infection and COVID-19 statistical report 30 November 2022 , 2022 .

[2] J. Stephenson. FDA Authorizes Pharmacists to Prescribe Oral Antiviral Medication for COVID-19. , 2022, JAMA Health Forum.

[3] M. Baniecki,et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[4] L. Ratner,et al. Nirmatrelvir/ritonavir use: Managing clinically significant drug‐drug interactions with transplant immunosuppressants , 2022, American Journal of Transplantation.

[5] M. Battegay,et al. Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID‐19 Patients , 2021, Clinical pharmacology and therapeutics.

[6] C. Silvestri,et al. Treatment for COVID-19: An overview , 2020, European Journal of Pharmacology.

[7] G. Mikus,et al. Concentration effect relationship of CYP3A inhibition by ritonavir in humans , 2013, European Journal of Clinical Pharmacology.

[8] Y. Cheung,et al. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations , 2003, European Journal of Clinical Pharmacology.

[9] Shufeng Zhou. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.